Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic plaque type psoriasis having body surface area involvement of \> 20%~* Patients of either sex~* Females who have completed their family and are tubectomized or are postmenopausal i.e. no menstrual bleeding over at least 1 year~* Age range 18-65 years~Exclusion Criteria:~* Females of child bearing potential~* H/O hypersensitivity to acitretin~* Impaired hepatic function (serum bilirubin, AST, ALT and alkaline phosphatase \>1.5 times the upper limit of normal)~* Impaired renal function (serum creatinine \>1.5mg% in males and \>1.4 mg% in females)~* Hyperlipidemia~* BMI \>30 kg /m2~* H/O excessive alcohol use~* Diabetes mellitus~* Congestive heart failure~* Ischemic heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Acitretin
- Experimental (Type: EXPERIMENTAL): Pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).